Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Signaling pathways regulating gliomagenesis.

Konopka G, Bonni A.

Curr Mol Med. 2003 Feb;3(1):73-84. Review.

PMID:
12558076
[PubMed - indexed for MEDLINE]
2.

Molecular mechanisms in gliomagenesis.

Hulleman E, Helin K.

Adv Cancer Res. 2005;94:1-27. Review.

PMID:
16095998
[PubMed - indexed for MEDLINE]
3.

Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?

Hlobilkova A, Ehrmann J, Sedlakova E, Krejci V, Knizetova P, Fiuraskova M, Kala M, Kalita O, Kolar Z.

Neoplasma. 2007;54(4):334-41.

PMID:
17822324
[PubMed - indexed for MEDLINE]
4.

Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Besson A, Yong VW.

J Neurooncol. 2001 Feb;51(3):245-64. Review.

PMID:
11407596
[PubMed - indexed for MEDLINE]
5.

Altered molecular pathways in gliomas: an overview of clinically relevant issues.

Rao RD, James CD.

Semin Oncol. 2004 Oct;31(5):595-604. Review.

PMID:
15497113
[PubMed - indexed for MEDLINE]
6.

PTEN signaling pathways in glioblastoma.

Koul D.

Cancer Biol Ther. 2008 Sep;7(9):1321-5. Epub 2008 Sep 8. Review.

PMID:
18836294
[PubMed - indexed for MEDLINE]
Free Article
7.

PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas.

Idoate MA, Soria E, Lozano MD, Sola JJ, Panizo A, de Alava E, Manrique M, Pardo-Mindán FJ.

Diagn Mol Pathol. 2003 Sep;12(3):160-5.

PMID:
12960698
[PubMed - indexed for MEDLINE]
8.

The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies.

Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP.

Neurology. 1998 Nov;51(5):1250-5. Review.

PMID:
9818841
[PubMed - indexed for MEDLINE]
9.

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.

Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6. doi: 10.1073/pnas.0813314106. Epub 2009 Feb 5.

PMID:
19196966
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
[PubMed - indexed for MEDLINE]
11.

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG.

BMC Med. 2008 Jun 24;6:14. doi: 10.1186/1741-7015-6-14.

PMID:
18577219
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches.

Kapoor GS, O'Rourke DM.

Cancer Biol Ther. 2003 Jul-Aug;2(4):330-42. Review.

PMID:
14508101
[PubMed - indexed for MEDLINE]
Free Article
13.

Genetic alterations and signaling pathways in the evolution of gliomas.

Ohgaki H, Kleihues P.

Cancer Sci. 2009 Dec;100(12):2235-41. doi: 10.1111/j.1349-7006.2009.01308.x. Epub 2009 Aug 6. Review.

PMID:
19737147
[PubMed - indexed for MEDLINE]
14.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Epub 2008 Jun 10. Review. French.

PMID:
18565348
[PubMed - indexed for MEDLINE]
15.

Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.

Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO.

Cancer Res. 2001 Jul 1;61(13):4956-60.

PMID:
11431323
[PubMed - indexed for MEDLINE]
Free Article
16.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
[PubMed - indexed for MEDLINE]
17.

Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.

Wang J, Ouyang W, Li J, Wei L, Ma Q, Zhang Z, Tong Q, He J, Huang C.

Cancer Res. 2005 Aug 1;65(15):6601-11.

PMID:
16061640
[PubMed - indexed for MEDLINE]
Free Article
18.

The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats.

Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, Rosenblum M, Holland EC.

Neoplasia. 2005 Apr;7(4):397-406.

PMID:
15967117
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Genetic analysis of a multifocal glioblastoma multiforme: a suitable tool to gain new aspects in glioma development.

Krex D, Mohr B, Appelt H, Schackert HK, Schackert G.

Neurosurgery. 2003 Dec;53(6):1377-84; discussion 1384.

PMID:
14633303
[PubMed - indexed for MEDLINE]
20.

PTEN and myotubularin phosphoinositide phosphatases: bringing bioinformatics to the lab bench.

Wishart MJ, Taylor GS, Slama JT, Dixon JE.

Curr Opin Cell Biol. 2001 Apr;13(2):172-81. Review.

PMID:
11248551
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk